tada, in this instance I’m not sure that I can agree that the sum of the parts is greater than the whole. Management has had very little success in unlocking value from either of these companies. RVX trades at about 15% of managements estimated EV where many companies trade at a premium to estimated EV (ESPR trades at about 115% of estimated EV currently).  Management at Zenith says it is worth somewhere around $3 US/share the best they have done in financing is $1/share and that’s throwing in dilution of the RVX preferreds, something which management said would cease to happen I believe two dilutions ago. Not very confidence inspiring. Perhaps one single epigenetic company of scientific excellence could inspire the market a little more thus leading to better valuations and potentially less dilutive financings for all involved. I think more irons in the fire for one company would result in lessened perceived risk. But just my opinion, I respect that others here see this differently.

I think that although Abbvies entry into epigenetics gives the field more credibility the fact that their entry is a BD-2 selective cancer therapy makes me wonder if Apabetalone is in fact competing with ZEN-3694 at least in some respects and further where down the road the companies may wind up head to head. I hope for the day when professional independent analysts could give an informed opinion on this. I guess for me, as a holder of both companies, I would like to see the most efficient and financially effective way forward for both companies.  I would love to see, as you suggest, something sold in the near future, preferably resulting in tangible shareholder benefit. Other than that I would like to see one public, industry leading company with the side result of the RVX preferred stock being distributed directly to current Zenith shareholders on a pro rata basis thus ending the dilution of those shares. (That’s probably dreaming but what the heck)